(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 November 2010 (18.11.2010)

PCT

(10) International Publication Number
WO 2010/131452 A1

(51) International Patent Classification:
C07K 7/06 (2006.01) *C07K 16/18* (2006.01)
A61K 38/00 (2006.01) *C12N 15/09* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/JP2010/003166

(22) International Filing Date:
10 May 2010 (10.05.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/216,017 11 May 2009 (11.05.2009) US

(71) Applicant *(for all designated States except US)*: **ONCOTHERAPY SCIENCE, INC.** [JP/JP]; 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa, 2130012 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **NAKAMURA, Yusuke** [JP/JP]; c/o THE UNIVERSITY OF TOKYO, 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo, 1138654 (JP). **TSUNODA, Takuya** [JP/JP]; c/o ONCOTHERAPY SCIENCE, INC., 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa, 2130012 (JP). **OHSAWA, Ryuji** [JP/JP]; c/o ONCOTHERAPY SCIENCE, INC., 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa, 2130012 (JP). **YOSHIMURA, Sachiko** [JP/JP]; c/o ONCOTHERAPY SCIENCE, INC., 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa, 2130012 (JP). **WATANABE, Tomohisa** [JP/JP]; c/o ONCOTHERAPY SCIENCE, INC., 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa, 2130012 (JP).

(74) Agents: **SHIMIZU, Hatsushi** et al.; Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki, 3000847 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2010/131452 A1

(54) **Title**: TTK PEPTIDES AND VACCINES INCLUDING THE SAME

(57) **Abstract**: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.